Caplin Point Reports Strong Q2 FY27 Consolidated Results with PAT Growth of 13.8% YoY
Caplin Point Laboratories Ltd · Financial Result · 12 Nov 2026, 6:45 pm
Caplin Point Reports Strong Q2 FY27 Consolidated Results with PAT Growth of 13.8% YoY Caplin Point Laboratories reported consolidated revenue from operations of ₹629.84 Cr for Q2 FY27, up 17.9% YoY and 3.2% QoQ, with EBITDA rising 16.8% YoY to ₹256.51 Cr (38.7% margin) and PAT growing 13.8% YoY to ₹182.35 Cr. For H1 FY27, revenue reached ₹1,240.20 Cr (+18.8% YoY) and PAT reached ₹361.42 Cr (+16.2% YoY). Free cash reserves stood at ₹1,534 Cr as of 30th Sep'26, fully funding its ongoing ₹1,000+ Cr capex plan via internal accruals.
Original exchange filing (PDF)
More announcements from Caplin Point Laboratories Ltd
- Classification of US FDA Inspection at the facility of Caplin Steriles Limited, subsidiary of the Company as OAI · 17 Nov 2026
- Audio Recording of Earnings call for the Quarter and half year ended September 30, 2026 · 13 Nov 2026
- Investor Presentation for the Earnings Call for the Quarter and half year ended September 30, 2026 · 12 Nov 2026
- Board Meeting Outcome for Meeting Held on November 12, 2026 · 12 Nov 2026
- Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- Analyst / investor Call for the quarter and half ended September 30, 2026 · 12 Nov 2026
- CAPLIN POINT LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 12 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 12 Nov 2026
